




Instance: composition-en-b0e9ca3c0296dbd9d61e291d9ccda718
InstanceOf: CompositionUvEpi
Title: "Composition for rasagiline Package Leaflet"
Description:  "Composition for rasagiline Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp24eee683e6bf399402c6c543711b22d7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - rasagiline"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Rasagiline ratiopharm is and what it is used for </li>
<li>What you need to know before you take Rasagiline ratiopharm </li>
<li>How to take Rasagiline ratiopharm </li>
<li>Possible side effects </li>
<li>How to store Rasagiline ratiopharm </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What rasagiline is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What rasagiline is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Rasagiline ratiopharm contains the active substance rasagiline and it is used for the treatment of 
Parkinson s disease in adults. It can be used together with or without Levodopa (another medicine that is 
used to treat Parkinson s disease). </p>
<p>With Parkinson s disease, there is a loss of cells that produce dopamine in the brain. Dopamine is a 
chemical in the brain involved in movement control. Rasagiline ratiopharm helps to increase and sustain 
levels of dopamine in the brain. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take rasagiline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take rasagiline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Rasagiline ratiopharm 
- If you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6). 
- If you have severe liver problems.  </p>
<p>Do not take the following medicines while taking Rasagiline ratiopharm:</p>
<ul>
<li>Monoamine oxidase (MAO) inhibitors (e.g. for treatment of depression or Parkinson s disease, or 
used for any other indication), including medicinal and natural products without prescription e.g. 
St. John's Wort. </li>
<li>Pethidine (a strong pain killer). 
You must wait at least 14 days after stopping Rasagiline ratiopharm treatment and starting treatment with 
MAO inhibitors or pethidine. </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor before taking Rasagiline ratiopharm 
- If you have any liver problems 
- You should speak with your doctor about any suspicious skin changes. Treatment 
with Rasagiline ratiopharm may possibly increase the risk of skin cancer. </p>
<p>Tell your doctor if you or your family/carer notices that you are developing unusual behaviours where 
you cannot resist the impulse, urges or cravings to carry out certain harmful or detrimental activities to 
yourself or others. These are called impulse control disorders. In patients taking Rasagiline ratiopharm 
and/or other medicines used to treat Parkinson s disease, behaviours such as compulsions, obsessive 
thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive 
or an increase in sexual thoughts or feelings have been observed. Your doctor may need to adjust or stop 
your dose (see section 4). </p>
<p>Rasagiline ratiopharm may cause drowsiness and may cause you to suddenly fall asleep 
during day time activities, especially if you are taking other dopaminergic medicinal 
products (used for the treatment of Parkinson s disease). For further information please 
refer to section driving and using machines. </p>
<p>Children and adolescents 
There is no relevant use of Rasagiline ratiopharm in children and adolescents. Therefore, Rasagiline 
ratiopharm is not recommended for use under the age of 18. Other medicines and Rasagiline ratiopharm 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. </p>
<p>Especially tell your doctor if you are taking any of the following medicines:</p>
<ul>
<li>Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine 
reuptake inhibitors, tricyclic or tetracyclic antidepressants)  </li>
<li>The antibiotic ciprofloxacin used against infections </li>
<li>The cough suppressant dextromethorphan </li>
<li>Sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold 
medicine containing ephedrine or pseudoephedrine 
The use of Rasagiline ratiopharm together with the antidepressants containing fluoxetine or fluvoxamine 
should be avoided. 
If you are starting treatment with Rasagiline ratiopharm, you should wait at least 5 weeks after stopping 
fluoxetine treatment. 
If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after 
stopping Rasagiline ratiopharm treatment. </li>
</ul>
<p>Tell your doctor or pharmacist if you are smoking or intend to stop smoking. Smoking could decrease the 
amount of Rasagiline ratiopharm in the blood. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine.  </p>
<p>You should avoid taking Rasagiline ratiopharm if you are pregnant, as the effects of Rasagiline 
ratiopharm on pregnancy and the unborn child are not known. </p>
<p>Driving and using machines 
Ask your doctor for advice before you drive and operate machines, since Parkinson s disease itself as 
well as the treatment with Rasagiline ratiopharm may influence your ability to do so. Rasagiline 
ratiopharm can make you feel dizzy or drowsy; it can also cause episodes of sudden sleep onset. 
This might be enhanced if you take other medicines to treat the symptoms of your Parkinson s disease, or 
if you take medicines which can make you feel drowsy, or if you drink alcohol while taking Rasagiline 
ratiopharm. If you have experienced somnolence and/or episodes of sudden sleep onset before, or while 
taking Rasagiline ratiopharm do not drive or operate machinery (see section 2). </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take rasagiline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take rasagiline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or 
pharmacist if you are not sure. </p>
<p>The recommended dose of Rasagiline ratiopharm is 1 tablet of 1 mg taken by mouth once daily. 
Rasagiline ratiopharm may be taken with or without food.  </p>
<p>If you take more Rasagiline ratiopharm than you should 
If you think that you may have taken too many Rasagiline ratiopharm tablets, contact your doctor or 
pharmacist immediately. Take the Rasagiline ratiopharm carton/ blister or bottle with you to show the 
doctor or pharmacist. </p>
<p>Symptoms reported following overdose of Rasagiline ratiopharm included slightly euphoric mood (light 
form of mania), extremely high blood pressure and serotonin syndrome (see section 4). </p>
<p>If you forget to take Rasagiline ratiopharm 
Do not take a double dose to make up for a forgotten dose. Take the next dose normally, when it is time 
to take it. </p>
<p>If you stop taking Rasagiline ratiopharm 
Do not stop taking Rasagiline ratiopharm without first talking to your doctor.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Contact you doctor right away if you notice any of the following symptoms. You may need urgent 
medical advice or treatment:</p>
<ul>
<li>If you develop unusual behaviours such as compulsions, obsessive thoughts, addictive gambling, 
excessive shopping or spending, impulsive behaviour and an abnormally high sex drive or an 
increase in sexual thoughts (impulse control disorders) (see section 2). </li>
<li>If you see or hear things which are not there (hallucinations). </li>
<li>Any combination of hallucinations, fever, restlessness, tremor and sweating (serotonin syndrome) </li>
</ul>
<p>Contact your doctor if you notice any suspicious skin changes because there may be an increased risk of 
skin cancer (melanoma) with the use of this medicine (see section 2). </p>
<p>Other side effects </p>
<p>Very common (may affect more than 1 in 10 people) 
- Involuntary movements (dyskinesia) 
- Headache </p>
<p>Common (may affect up to 1 in 10 people) 
- Abdominal pain 
- Fall 
- Allergy 
- Fever 
- Flu (influenza) 
- General feeling of being unwell (malaise) 
- Neck pain 
- Chest pain (angina pectoris) 
- Low blood pressure when rising to a standing position with symptoms like dizziness/light-
headedness (orthostatic hypotension) 
- Decreased appetite<br />
- Constipation 
- Dry mouth 
- Nausea and vomiting 
- Flatulence 
- Abnormal results of blood tests (leucopenia) 
- Joint pain (arthralgia) 
- Musculoskeletal pain 
- Joint inflammation (arthritis) 
- Numbness and muscle weakness of the hand (carpal tunnel syndrome) 
- Decreased weight<br />
- Abnormal dreams 
- Difficulty in muscular coordination (balance disorder) 
- Depression 
- Dizziness (vertigo) 
- Prolonged muscle contractions (dystonia) 
- Runny nose (rhinitis) 
- Irritation of the skin (dermatitis)<br />
- Rash 
- Bloodshot eyes (conjunctivitis) 
- Urinary urgency </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- Stroke (cerebrovascular accident) 
- Heart attack (myocardial infarction) 
- Blistering rash (vesiculobullous rash) </p>
<p>Not known: frequency cannot be estimated from the available data<br />
- Elevated blood pressure 
- Excessive drowsiness 
- Sudden onset of sleep </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store rasagiline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store rasagiline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after EXP. 
The expiry date refers to the last day of that month.  </p>
<p>Do not store above 30oC. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Rasagiline ratiopharm contains 
- The active substance is rasagiline. Each tablet contains 1 mg rasagiline (as mesilate). 
- The other ingredients are mannitol, colloidal anhydrous silica, maize starch, pregelatinised maize 
starch, stearic acid, talc. </p>
<p>What Rasagiline ratiopharm looks like and contents of the pack 
Rasagiline ratiopharm tablets are presented as white to off-white, round, flat, bevelled tablets, debossed 
with  GIL  and  1  underneath on one side and plain on the other side. </p>
<p>The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets, in perforated unit dose 
blister packs of 10 x 1, 30 x 1 and 100 x 1 tablets or in a bottle containing 30 tablets. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>Teva B.V. 
Swensweg 5 
2031 GA Haarlem 
Netherlands </p>
<p>Manufacturers </p>
<p>Teva Pharmaceuticals Europe B.V. 
Swensweg 5 
2031 GA Haarlem 
Netherlands </p>
<p>Pliva Croatia Ltd. 
Prilaz baruna Filipovica 10000 Zagreb 
Croatia </p>
<p>Teva Operations Poland Sp.z o.o. 
ul. Mogilska 31-546 Krakow 
Poland </p>
<p>For any information about this medicinal product, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
T l/Tel: +32 38207Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>Te : +359 24899Luxembourg/Luxemburg 
Teva Pharma Belgium N.V./S.A./AG 
Belgique/Belgien<br />
T l/Tel: +32 38207 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
ratiopharm GmbH 
Tel: +49 73140Nederland 
Teva Nederland B.V. 
Tel: +31 8000228Eesti 
Norge 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Teva Norway AS<br />
Tlf: +47 66775<br />
Specifar A.B.E.E. 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Laboratorios Davur, S.L.U. 
Tel: +34 913873Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Teva Sant<br />
T l: +33 155917Portugal 
Teva Pharma - Produtos Farmac uticos, Lda. 
Tel: +351 214767Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Teva Pharma Iceland ehf. 
S mi: +354 5503Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Teva Italia S.r.l. 
Tel: +39 028917Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
Specifar A.B.E.E. </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij <br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407This leaflet was last revised in MM/YYYY. </p>         </div>"""      



Instance: composition-da-b0e9ca3c0296dbd9d61e291d9ccda718
InstanceOf: CompositionUvEpi
Title: "Composition for rasagiline Package Leaflet"
Description:  "Composition for rasagiline Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp24eee683e6bf399402c6c543711b22d7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - rasagiline"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Rasagilin ratiopharm 
3. Sådan skal De tage Rasagilin ratiopharm 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What rasagiline is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What rasagiline is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Rasagilin ratiopharm indeholder det aktive stof rasagilin og anvendes til behandling af Parkinsons 
sygdom hos voksne. Det kan bruges sammen med eller uden levodopa (et andet lægemiddel, som 
anvendes til behandling af Parkinsons sygdom). </p>
<p>Parkinsons sygdom forårsager et tab af celler, som producerer dopamin i hjernen. Dopamin er et stof i 
hjernen, som er med til at styre bevægelser. Rasagilin ratiopharm er med til at øge og opretholde 
dopaminniveauet i hjernen.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take rasagiline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take rasagiline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Rasagilin ratiopharm 
- hvis De er allergisk over for rasagilin eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6). 
- hvis De lider af alvorlige leverlidelser. </p>
<p>Tag ikke følgende lægemidler, mens De er i behandling med Rasagilin ratiopharm:</p>
<ul>
<li>Monoaminooxidasehæmmere (MAO-hæmmere) (f.eks. til behandling af depression eller 
Parkinsons sygdom eller til behandling af andre lidelser), inkl. lægemidler eller naturlægemidler i 
håndkøb, som f.eks. perikon </li>
<li>Pethidin (et stærkt smertestillende lægemiddel) 
Der skal gå mindst 14 dage, efter at De er stoppet med Deres behandling med Rasagilin ratiopharm, 
før De må påbegynde en behandling med MAO-hæmmere eller pethidin. </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før De tager Rasagilin ratiopharm 
- hvis De har leverproblemer 
- hvis De får mistænkelige hudforandringer, skal De tale med Deres læge. Behandlingen med 
Rasagilin ratiopharm kan muligvis øge risikoen for hudkræft. </p>
<p>Fortæl det til lægen, hvis De eller Deres familie/omsorgsperson bemærker, at De er ved at udvikle en 
usædvanlig adfærd, hvor De ikke kan modstå lysten, fristelsen eller trangen til at udføre bestemte 
handlinger, der er uønskede eller skadelige for Dem selv eller andre. En sådan adfærd kaldes 
impulskontrolforstyrrelser. Hos patienter i behandling med Rasagilin ratiopharm og/eller andre 
lægemidler til behandling af Parkinsons sygdom er der set tvangshandlinger, tvangstanker, 
afhængighedspræget spillelyst, overdrevent pengeforbrug, impulshandling og en unormalt stor sexlyst 
eller en stigning i seksuelle tanker og følelser. Lægen kan være nødt til at ændre Deres dosis eller 
stoppe behandlingen (se punkt 4). </p>
<p>Rasagilin ratiopharm kan forårsage døsighed, og at du pludselig falder i søvn under 
daglige aktiviteter, især hvis du tager andre dopaminerge lægemidler (anvendes til 
behandling af Parkinsons sygdom). Se yderligere oplysninger i punktet om at føre 
motorkøretøj og betjene maskiner. </p>
<p>Børn og unge 
Der er ingen relevant brug af Rasagilin ratiopharm til børn og unge. Rasagilin ratiopharm anbefales 
derfor ikke til unge under 18 år. </p>
<p>Brug af anden medicin sammen med Rasagilin ratiopharm 
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin eller har brugt det for 
nylig. </p>
<p>Fortæl det især til Deres læge, inden De tager et af følgende lægemidler:</p>
<ul>
<li>Visse former for lægemidler til behandling af depression (selektive 
serotoningenoptagelseshæmmere, selektive serotonin-/noradrenalingenoptagelseshæmmere, 
tricykliske eller tetracykliske antidepressive lægemidler) </li>
<li>Antibiotikummet ciprofloxacin til behandling af infektioner </li>
<li>Det hostestillende middel dextromethorphan </li>
<li>Øjendråber, næsedråber/-spray og slimløsende lægemidler til næse og svælg, der indeholder 
sympatomimetika, samt forkølelsesmedicin, der indeholder ephedrin eller pseudoephedrin 
Rasagilin ratiopharm bør ikke indtages sammen med antidepressive lægemidler, der indeholder 
fluoxetin eller fluvoxamin. 
De skal vente mindst 5 uger efter at have stoppet behandling med fluoxetin, inden De påbegynder 
behandling med Rasagilin ratiopharm. 
De skal vente mindst 14 dage efter at have stoppet behandling med Rasagilin ratiopharm, inden De 
påbegynder behandling med fluoxetin eller fluvoxamin. </li>
</ul>
<p>Fortæl det til lægen eller apotekspersonalet, hvis De ryger eller har til hensigt at holde op med at ryge. 
Rygning kan nedsætte mængden af Rasagilin ratiopharm i blodet. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Du skal undgå at tage Rasagilin ratiopharm, hvis du er gravid, da virkningen af Rasagilin ratiopharm 
på graviditeten og det ufødte barn er ukendt. </p>
<p>Trafik- og arbejdssikkerhed 
Spørg Deres læge til råds, inden De kører bil, og inden De arbejder med maskiner, da Parkinsons 
sygdom tillige med behandlingen med Rasagilin ratiopharm kan påvirke evnen til at udføre disse 
handlinger. Rasagilin ratiopharm kan få Dem til at føle svimmelhed eller døsighed. Lægemidlet kan 
også forårsage episoder med pludseligt opstået søvn. 
Dette kan forstærkes, hvis De tager anden medicin til behandling af Deres symptomer på Parkinsons 
sygdom, eller hvis De tager medicin, som kan få Dem til at føle døsighed, eller hvis De drikker 
alkohol, mens De tager Rasagilin ratiopharm. Hvis De har oplevet søvnighed og/eller episoder med </p>
<p>pludseligt opstået søvn før, eller mens De tager Rasagilin ratiopharm, skal De undlade at køre bil eller 
betjene maskiner (se punkt 2). </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take rasagiline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take rasagiline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er De i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er 1 tablet (1 mg) Rasagilin ratiopharm én gang dagligt. Tabletten indtages 
gennem munden. Rasagilin ratiopharm kan tages i forbindelse med et måltid eller uden for måltiderne. </p>
<p>Hvis De har taget for meget Rasagilin ratiopharm 
Hvis De mener, at De har taget for mange Rasagilin ratiopharm tabletter, skal De straks kontakte 
Deres læge eller apotekspersonalet. Medbring Rasagilin ratiopharm æsken/blisterpakningen eller 
beholderen, når De opsøger Deres læge/skadestue eller apotekspersonalet. </p>
<p>Rapporterede symptomer efter en overdosering af Rasagilin ratiopharm omfattede let eufori (let form 
for mani), ekstremt højt blodtryk og serotoninsyndrom (se punkt 4). </p>
<p>Hvis De har glemt at tage Rasagilin ratiopharm 
De må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Tag den næste dosis på det 
tidspunkt, hvor De normalt tager Deres Rasagilin ratiopharm. </p>
<p>Hvis De holder op med at tage Rasagilin ratiopharm 
Hold ikke op med at tage Rasagilin ratiopharm uden først at have talt med Deres læge om det. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Kontakt omgående Deres læge, hvis De bemærker nogen af følgende symptomer. De kan have 
behov for akut lægehjælp eller -behandling:</p>
<ul>
<li>Hvis De udvikler usædvanlig adfærd som f.eks. tvangshandlinger, tvangstanker, ludomani, 
uhæmmet, umådeholdent indkøb eller forbrug, impulshandlinger og en unormalt stor sexlyst 
eller en stigning i seksuelle tanker (impulskontrolforstyrrelser) (se punkt 2). </li>
<li>Hvis De ser eller hører ting, der ikke er der (hallucinationer). </li>
<li>Enhver kombination af hallucinationer, feber, rastløshed, rysten og svenden (serotoninsyndrom) </li>
</ul>
<p>Kontakt Deres læge, hvis De bemærker nogen mistænkelige hudforandringer, fordi der kan være en 
forhøjet risiko for hudkræft (melanom), når dette lægemiddel anvendes (se punkt 2). </p>
<p>Andre bivirkninger </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) 
- Ufrivillige bevægelser (dyskinesi) 
- Hovedpine </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer 
- Mavesmerter 
- Fald 
- Allergi 
- Feber </p>
<ul>
<li>Influenza </li>
<li>En følelse af at være sløj (utilpashed) </li>
<li>Nakkesmerter </li>
<li>Smerter i brystet (angina pectoris) </li>
<li>Blodtryksfald ved hurtig ændring fra liggende/siddende til stående stilling med symptomer som 
svimmelhed (ortostatisk hypotension) </li>
<li>Nedsat appetit </li>
<li>Forstoppelse </li>
<li>Mundtørhed </li>
<li>Kvalme og opkastning </li>
<li>Luftafgang fra tarmen </li>
<li>Unormale blodprøveresultater (leukopeni (nedsat antal hvide blodlegemer)) </li>
<li>Ledsmerter (artralgi) </li>
<li>Smerter i muskler og led </li>
<li>Betændelsestilstand i led (artritis) </li>
<li>Følelsesløshed og kraftesløshed i musklerne i hånden (karpaltunnelsyndrom) </li>
<li>Vægttab </li>
<li>Unormale drømme </li>
<li>Manglende koordination af bevægelser (balanceforstyrrelser) </li>
<li>Depression </li>
<li>Svimmelhed </li>
<li>Ufrivillige bevægelser af kroppen (dystoni) </li>
<li>Løbenæse (snue) </li>
<li>Irritation af huden (dermatitis) </li>
<li>Udslæt </li>
<li>Øjenbetændelse med røde øjne (conjunctivitis) </li>
<li>Pludseligt opstået vandladningstrang. </li>
</ul>
<p>Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) 
- Slagtilfælde (cerebrovaskulært tilfælde) 
- Hjerteanfald (myokardieinfarkt) 
- Udslæt med blæredannelse (vesikulobulbært udslæt) </p>
<p>Ikke kendt (hyppighed kan ikke vurderes ud fra forhåndenværende data) 
- Forhøjet blodtryk 
- Overdreven døsighed 
- Pludselig indsovning </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store rasagiline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store rasagiline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken, beholderen eller blisterpakningen efter 
Exp. Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 oC. </p>
<p>Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Rasagilin ratiopharm indeholder:</p>
<ul>
<li>Aktivt stof: Rasagilin. Hver tablet indeholder 1 mg rasagilin (som mesilat). </li>
<li>Øvrige indholdsstoffer: Mannitol, kolloid vandfri silica, majsstivelse, prægelatineret 
majsstivelse, stearinsyre, talkum. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Rasagilin ratiopharm tabletter fås som hvide til grålighvide, runde, flade tabletter med skrå kant, 
præget på den ene side med "GIL" og nedenunder "1" og uden præg på den anden side. </p>
<p>Tabletterne findes i blisterpakninger med 7, 10, 28, 30, 100 og 112 tabletter, i perforerede 
enkeltdosisblisterpakninger med 10 x 1, 30 x 1 og 100 x 1 tabletter eller i en beholder med 
30 tabletter.<br />
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Teva B.V. 
Swensweg 5 
2031 GA Haarlem 
Holland </p>
<p>Fremstillere </p>
<p>Teva Pharmaceuticals Europe B.V. 
Swensweg 5 
2031 GA Haarlem 
Holland </p>
<p>Pliva Croatia Ltd. 
Prilaz baruna Filipovica 10000 Zagreb 
Kroatien </p>
<p>Teva Operations Poland Sp. z o.o. 
ul. Mogilska 31-546 Krakow 
Polen </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
Tél/Tel: +32 38207 
Lietuva 
UAB Teva Baltics 
Tel: +370 52660 
България 
Тева Фарма ЕАД 
Teл: +359 24899 
Luxembourg/Luxemburg 
Teva Pharma Belgium N.V./S.A./AG 
Belgique/Belgien<br />
Tél/Tel: +32 38207 </p>
<p>Česká republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007 
Magyarország 
Teva Gyógyszergyár Zrt. 
Tel: +36 12886 
Danmark 
Teva Denmark A/S 
Tlf: +45 44985 
Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407 
Deutschland 
ratiopharm GmbH 
Tel: +49 73140 
Nederland 
Teva Nederland B.V. 
Tel: +31 8000228 
Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610 
Norge 
Teva Norway AS<br />
Tlf: +47 66775 
Ελλάδα 
Specifar A.B.E.E. 
Τηλ: +30 2118805 
Österreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970 
España 
Laboratorios Davur, S.L.U. 
Tel: +34 913873 
Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459 
France 
Teva Santé 
Tél: +33 155917 
Portugal 
Teva Pharma - Produtos Farmacêuticos, Lda. 
Tel: +351 214767 
Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720 
România 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306 
Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407 
Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 
Ísland 
Teva Pharma Iceland ehf. 
Sími: +354 5503 
Slovenská republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267 
Italia 
Teva Italia S.r.l. 
Tel: +39 028917 
Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805 
Κύπρος 
Specifar A.B.E.E. 
Ελλάδα 
Τηλ: +30 2118805 
Sverige 
Teva Sweden AB 
Tel: +46 42121 
Latvija 
UAB Teva Baltics filiāle Latvijā<br />
Tel: +371 67323 
United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407 </p>
<p>Denne indlægsseddel blev senest ændret måned/ÅÅÅÅ.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-b0e9ca3c0296dbd9d61e291d9ccda718
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for rasagiline Package Leaflet for language en"
Description: "ePI document Bundle for rasagiline Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-b0e9ca3c0296dbd9d61e291d9ccda718"
* entry[0].resource = composition-en-b0e9ca3c0296dbd9d61e291d9ccda718

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0e9ca3c0296dbd9d61e291d9ccda718"
* entry[=].resource = mpb0e9ca3c0296dbd9d61e291d9ccda718
                            
                    
Instance: bundlepackageleaflet-da-b0e9ca3c0296dbd9d61e291d9ccda718
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for rasagiline Package Leaflet for language da"
Description: "ePI document Bundle for rasagiline Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-b0e9ca3c0296dbd9d61e291d9ccda718"
* entry[0].resource = composition-da-b0e9ca3c0296dbd9d61e291d9ccda718

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0e9ca3c0296dbd9d61e291d9ccda718"
* entry[=].resource = mpb0e9ca3c0296dbd9d61e291d9ccda718
                            
                    



Instance: mpb0e9ca3c0296dbd9d61e291d9ccda718
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product rasagiline"
Description: "rasagiline"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/14/977/001-010"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Rasagiline ratiopharm is indicated in adults for the treatment of idiopathic Parkinson’s disease as"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "rasagiline"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: b0e9ca3c0296dbd9d61e291d9ccda718ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "rasagiline"

* status = #current
* mode = #working

* title = "List of all ePIs associated with rasagiline"

* subject = Reference(mp24eee683e6bf399402c6c543711b22d7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#rasagiline "rasagiline"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-b0e9ca3c0296dbd9d61e291d9ccda718) // rasagiline en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-b0e9ca3c0296dbd9d61e291d9ccda718) // rasagiline da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-b0e9ca3c0296dbd9d61e291d9ccda718
InstanceOf: List

* insert b0e9ca3c0296dbd9d61e291d9ccda718ListRuleset
    